Foghorn Therapeutics Inc. stock is up 164.19% since 30 days ago. The next earnings date is Mar 15, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 75% of the previous 3 March’s closed higher than February. In the last 1 Unusual Options Trades, there were 1 CALL.
Foghorn Therapeutics Inc. is developing a small molecule inhibitor of the enzymatic activity of BRG1 and BRM for the treatment of metastatic uveal melanoma and relapsed and/or refractory acute myeloid leukemia and myelodysplastic syndrome. The company is also developing an enzyme inhibitor and protein degrader as selective modulators of BRM.
Unlock Exclusive Market Insights! Receive timely updates on market developments. Sign up & stay informed!